PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population
PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population
复制标题
DOI：
10.1007/s11033-010-0236-6
复制
发表时间：
2011-02-01
影响因子：
2.8
通讯作者：
Jesus Coma del Corral, Maria
中科院分区：
文献类型：
--
作者：
Herreros-Villanueva, Marta;Gomez-Manero, Noemi;Jesus Coma del Corral, Maria
这项工作的目的是研究野生型KRAS和BRAF结直肠癌中的PIK 3CA突变。临床病理资料和石蜡包埋标本收集了73例接受结直肠切除术在总雅格医院在布尔戈斯。通过实时PCR分析所有患者的KRAS、BRAF和PIK 3CA状态。PIK 3CA突变存在于8.22%的野生型KRAS和BRAF结直肠癌中。最常见的突变是外显子9中的E545 K/D，占所有突变的83.3%。相比之下，我们没有发现任何肿瘤携带H1047 R突变的外显子20。在接受结直肠癌根治性切除术的患者中，PIK 3CA突变存在于重要百分比的KRAS和BRAF野生型肿瘤中。PIK 3CA突变可能被认为是对抗EGFR抗体无应答的假设原因。
The objective of the work was to study PIK3CA mutations in wild type KRAS and BRAF colorectal cancer. Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yague Hospital in Burgos. KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in all patients. PIK3CA mutations were present in 8.22% of wild type KRAS and BRAF colorectal cancers. The most frequent mutation is E545K/D in exon 9 which represents 83.3% of all mutations. By contrast, we did not found any tumour harbouring H1047R mutation in exon 20. Among the patients who undergo a curative resection of colorectal cancer, PIK3CA mutation is present in an important percentage of KRAS and BRAF wild type tumours. PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies.